PET Occupancy study of ABX-1431 in healthy volunteers

Trial Profile

PET Occupancy study of ABX-1431 in healthy volunteers

Phase of Trial: Phase I

Latest Information Update: 19 May 2016

At a glance

  • Drugs ABX 1431 (Primary)
  • Indications Central pain; Epilepsy; Neurogenic inflammation; Neurological disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 19 May 2016 New trial record
    • 10 May 2016 According to Abide Therapeutics media release, company announced the initiation of enrollment and dosing in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top